These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 24875859)

  • 21. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The democratization of the oncogene.
    Le AT; Doebele RC
    Cancer Discov; 2014 Aug; 4(8):870-2. PubMed ID: 25092743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
    Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
    Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
    Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
    Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
    Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
    Front Oncol; 2021; 11():658327. PubMed ID: 34211840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
    Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
    Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT).
    Sommer S; Schmutz M; Schaller T; Mayr P; Dintner S; Märkl B; Huss R; Golas MM; Kuhlen M; Jordan F; Claus R; Heinrich B
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1916. PubMed ID: 37950626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
    Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
    J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.
    Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA
    Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
    Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
    Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
    Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
    Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
    Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
    Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
    Liu X; Duan Y; Wang G; Zhu P
    Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor.
    Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X
    Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
    Ma Z; Hill DA; Collins MH; Morris SW; Sumegi J; Zhou M; Zuppan C; Bridge JA
    Genes Chromosomes Cancer; 2003 May; 37(1):98-105. PubMed ID: 12661011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
    Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
    Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.